Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)
Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults
Evidence-based recommendations on inhaled corticosteroids (ICSs) for chronic asthma in children aged under 12
Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma (bone marrow cancer)
Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids
Evidence-based recommendations on natalizumab (Tysabri) for highly active relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on pemetrexed (Alimta) for treating non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on varenicline (Champix) to help people stop smoking
Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)
Evidence-based recommendations on fludarabine (Fludara) monotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C
Evidence-based recommendations on the use of Riluzole (Rilutek) for treating motor neurone disease (MND)
Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis
Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)
Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor
Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on gefitinib (Iressa) for the first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC)
Evidence-based recommendation on capecitabine (Xeloda) for treating advanced (inoperable) gastric cancer (stomach cancer)
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism to treat people on dialysis who have kidney disease
Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer
Evidence-based recommendations on naltrexone (Nalorex) for the management of opioid dependence
Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C
Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults
Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer
Evidence-based recommendations on capecitabine (Xeloda) and oxaliplatin (Eloxatin) for adjuvant treatment of stage III (Dukes' C) colon (bowel) cancer
Evidence-based recommendations on routine antenatal anti-D prophylaxis for women who are rhesus D negative
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for the treatment of age-related macular degeneration (AMD)
Evidence-based recommendations on telbivudine (Sebivo) for the treatment of chronic hepatitis B
Evidence-based recommendations on entecavir (Baraclude) for the treatment of chronic hepatitis B
Evidence-based recommendations on drug-eluting stents for the treatment of coronary artery disease
Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis
Evidence-based recommendations on cetuximab (Erbitux) for the treatment of locally advanced squamous cell cancer of the head and neck
Evidence-based recommendations on continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnoea/hypopnoea syndrome
Evidence-based recommendations on the use of inhaler systems (devices) for chronic asthma in children under 5
Evidence-based recommendations on the extraction of wisdom teeth
Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma
Evidence-based recommendations on tisagenlecleucel therapy (Kymriah) for relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up 25 years
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over
Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in
Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults